Bone Marrow Stem Cell Therapy / Stem Cell Prolotherapy
Stem Cell Prolotherapy is a procedure in which adult mesenchymal stem cells are transplanted directly into the damaged tissue or injury and promotes healing. Stem cells are the repairmen...
By: Kab S. Hong M.D.
Read the rest here:
Bone Marrow Stem Cell Therapy / Stem Cell Prolotherapy - Video
Source: ISNA
Iran inaugurated the cell therapy and regenerative medicine center affiliated to the country's Red Crescent Society in a ceremony attended by Iranian Vice President for Science and Technology Affairs Sorena Sattari.
"Stem cells are of great importance for the future. If we want to describe the modern medicine, we should say that one of its important bases is stem cell," he said.
He also said scientific projects take 10-15 years to turn into trade products.
In 2013, Iran hosted an international congress on stem cell and biomedicine attended by representatives of major medical research groups mostly from China, India, Italy and US and Iran have taken part in the two-day event and was organized by Iran's Royan institute.
The congress aimed to bring together the researchers and practitioners from all over the world in stem cells and reproductive biomedicine to stimulate and promote research in this area.
Stem cell research is one of the most promising research areas in modern biomedicine. However, due to moral and ethical debates, it remains a controversial issue in many regions of the world.
Stem cells have been shown to have significant capability to develop into a plethora of different cell types and work as a repair system to replenish cells with specialized functions.
Due to the efforts of Iranian scientists, doctors, engineers and researchers, Iran has advanced tremendously in the fields of stem cell research, medicine, nanotechnology, biotechnology and aerospace engineering.
Read more:
Iran opens cell therapy center
Boston, MA (PRWEB) December 23, 2014
Earlier this year in a June 24 international conference presentation, Dr. James L. Sherley, director of the Adult Stem Cell Technology Center, LLC (ASCTC) focused attention on an often overlooked and under appreciated unique property of adult tissue stem cells. His title Asymmetric Self-Renewal by Distributed Stem Cells: Misunderstood in the Past, Important for the Future, embodied the essence of his message to congress participants. He gave the address at the 4th World Congress on Cell Science and Stem Cell Research in Valencia, Spain.
The international congress was organized by the Omics Group as a part of its mission to foster the dissemination of leading discoveries and advances in life sciences research. Their posting this month of the slides from Dr. Sherley's June 24 keynote address now provides worldwide open access to life sciences investigators - stem cell biologists in particular - of the concepts that he emphasized.
In a 2008 publication [Breast Disease 29, 37-46, 2008], Sherley coined the new term distributed stem cells (DSCs) as a biology-based name for all natural tissue stem cells that are not embryonic in origin. Adult stem cells are included under the DSC heading. DSCs do not make every cell in the body. Their nature is to produce only a limited tissue-specific or organ-specific distribution of the total possible mature cell types. So, for example, liver DSCs make mature liver cells, but not mature cells found in other organs like the lungs.
Since 2001 and the start of "the stem cell debate," Sherley has insisted that only DSCs can be effective for developing new cellular therapies. In his keynote address, he explained to attendees why the counterparts of DSCs human embryonic stem cells (hESCs) and more recently developed induced pluripotent stem cells (iPSCs) could not.
Though many stem cell scientists recognize and acknowledge the genetic defects, incomplete differentiation, and tumor formation problems of hESCs and iPSCs - which their proponents suggest can be solved - few appreciate their greater problem, which cannot be solved. Unlike DSCs, hESCs and iPSCs lack the property of asymmetric self-renewal.
Sherleys main message is that asymmetric self-renewal, which is the gnomonic for DSCs the very property that defines DSCs is essential for effective cellular therapies. Asymmetric self-renewal means that DSCs can actively multiply with simultaneous reproduction of themselves and production of mature cells. This ability allows DSCs to replenish mature cells, which are continuously lost from tissues and organs, but not lose their genetic blueprint required for tissue and organ renewal and repair.
The asymmetric self-renewal of DSCs is a crucial consideration for all aspects of their study and use. Sherley argues that overlooking it is holding back progress in regenerative medicine. Asymmetric self-renewal is the factor that limits the production of DSCs; but it is so unique to them that it can also be used to identify DSCs, which are notorious for being elusive. The ASCTCs patented technologies for producing and counting DSCs for research and clinical development are grounded in the companys special research and bioengineering expertise for DSC asymmetric self-renewal.
Asymmetric self-renewal may even play a role in the efficient production of iPSCs. At the end of his address, Sherley announced the approval of a new ASCTC patent. The patent covers the invention of a method to make iPSCs from DSCs that were produced by regulating their asymmetric self-renewal (U.S. Patent and Trademark Office No. 8,759,098).
The ASCTC anticipates that despite the new technologys origin in DSC research, it will advance human disease research based on iPSCs. Although iPSCs are not suitable for cell therapy applications, they are uniquely able to provide disease research models for hard to obtain cell types found in patients (e.g., brain cells from autism patients, cardiac cells from heart disease patients).
Follow this link:
Adult Stem Cell Technology Center, LLCs Director Sherley's Address on Whats Holding Back Regenerative Medicine ...
A new stem cell transplantation centre opened on Monday in the St. Marina hospital in Varna, reports the bTV national channel.
It is the most up-to-date in Bulgaria and is expected to partially solve the shortage of such treatment of patients with oncological diseases.
According to the head of the heaematology clinic of the St. Marina hospital, Riana Gercheva, the stem cell treatment often is a life-saving procedure for cancer patients whose bone marrow has been severely damaged by chemotherapy.
According to the deputy rector of the Varna Medical University, Deyan Grancharov, there are two similar centres in Sofia and Plovdiv, but the demand was much higher. Now it will be much cheaper and easily accessible than similar treatment in Israel, for example, Grancharov said.
The capacity of the Varna centre is up to 100 patients per year. The procedure is free of charge for the insured.
(New York City) A new test may reveal which patients will respond to treatment for graft versus host disease (GVHD), an often life-threatening complication of stem cell transplants (SCT) used to treat leukemia and other blood disorders, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai and published online today in the journal Lancet Haematology and in print in the January issue.
Patients with fatal blood cancers like leukemia often require allogenic stem cell SCT to survive. Donor stem cells are transplanted to a recipient, but not without the risk of developing GVHD, a life-threatening complication and major cause of death after SCT. The disease, which can be mild to severe, occurs when the transplanted donor cells (known as the graft) attack the patient (referred to as the host). Symptom severity, however, does not accurately define how patients will respond to treatment and patients are often treated alike with high-dose steroids. Although SCT cures cancer in 50 percent of the patients, 25 percent die from relapsed cancer and there remaining go into remission but later succumb to effects of GVHD.
"High dose steroids is the only proven treatment for GVHD," said James L. M. Ferrara, MD, DSc, Ward-Coleman Chair in Cancer Medicine Professor at the Icahn School of Medicine at Mount Sinai, Director of Hematologic Malignancies Translational Research Center at Tisch Cancer Institute at Mount Sinai. "Those with low-risk GVHD are often over-treated and face significant side-effects from treatment. Patients with high risk GVHD are undertreated and the GVHD progresses, often with fatal consequences. Our goal is to provide the right treatment for each patient. We hope to identify those patients at higher risk and design an aggressive intervention while tailoring a less-aggressive approach for those with low-risk."
Dr. Ferrara, along with a multi-center team of researchers, developed and tested this new scoring system using almost 500 patient blood samples with newly diagnosed GVHD in varying grades from two different centers. They used three validated biomarkers TNFR1, ST2 and Reg3 to create an algorithm that calculated the probability of non-relapse mortality (usually caused by GVHD) that provided three distinct risk scores to predict the patient's response to GVHD treatment.
The acid test was to evaluate the algorithm in a validation set of 300 additional patients from twenty different SCT centers throughout the US. The algorithm worked perfectly, and the cumulative incidence of non-relapse mortality significantly increased as the GVHD score increased, and so the response rate to primary GVHD treatment decreased.
"This new scoring system will help identify patient who may not respond to standard treatments, and may require an experimental and more aggressive approach," said Dr. Ferrara. "And it will also help guide treatment for patients with lower-risk GVHD who may be over-treated. This will allow us to personalize treatment at the onset of the disease. Future algorithms will prove increasingly useful to develop precision medicine for all SCT patients."
In order to capitalize on this discovery, Dr. Ferrara has created the Mount Sinai Acute GVHD International Consortium (MAGIC) which consists of a group of ten SCT centers in the US and Europe who will collaborate to use this new scoring system to test new treatments for acute GVHD. Dr. Ferrara and colleagues have also written a protocol to treat high-risk GVHD that has been approved by the FDA.
###
Co-collaborators included University of Michigan, University of Regensburg, and the Blood and Marrow Clinical Trials Network.
The study was supported by grants from the National Cancer Institute; the National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases, the Doris Duke Charitable Fund, the American Cancer Society, and the Judith Devries Fund.
Read the rest here:
Test predicts response to treatment for complication of leukemia stem cell treatment
Contact Information
Available for logged-in reporters only
Newswise (New York City) A new test may reveal which patients will respond to treatment for graft versus host disease (GVHD), an often life-threatening complication of stem cell transplants (SCT) used to treat leukemia and other blood disorders, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai and published online today in the journal Lancet Haematology and in print in the January issue.
Patients with fatal blood cancers like leukemia often require allogenic stem cell SCT to survive. Donor stem cells are transplanted to a recipient, but not without the risk of developing GVHD, a life-threatening complication and major cause of death after SCT. The disease, which can be mild to severe, occurs when the transplanted donor cells (known as the graft) attack the patient (referred to as the host). Symptom severity, however, does not accurately define how patients will respond to treatment and patients are often treated alike with high-dose steroids. Although SCT cures cancer in 50 percent of the patients, 25 percent die from relapsed cancer and there remaining go into remission but later succumb to effects of GVHD.
High dose steroids is the only proven treatment for GVHD, said James L. M. Ferrara, MD, DSc, Ward-Coleman Chair in Cancer Medicine Professor at the Icahn School of Medicine at Mount Sinai, Director of Hematologic Malignancies Translational Research Center at Tisch Cancer Institute at Mount Sinai. Those with low-risk GVHD are often over-treated and face significant side-effects from treatment. Patients with high risk GVHD are undertreated and the GVHD progresses, often with fatal consequences. Our goal is to provide the right treatment for each patient. We hope to identify those patients at higher risk and design an aggressive intervention while tailoring a less-aggressive approach for those with low-risk.
Dr. Ferrara, along with a multi-center team of researchers, developed and tested this new scoring system using almost 500 patient blood samples with newly diagnosed GVHD in varying grades from two different centers. They used three validated biomarkers TNFR1, ST2 and Reg3 to create an algorithm that calculated the probability of non-relapse mortality (usually caused by GVHD) that provided three distinct risk scores to predict the patients response to GVHD treatment.
The acid test was to evaluate the algorithm in a validation set of 300 additional patients from twenty different SCT centers throughout the US. The algorithm worked perfectly, and the cumulative incidence of non-relapse mortality significantly increased as the GVHD score increased, and so the response rate to primary GVHD treatment decreased.
This new scoring system will help identify patient who may not respond to standard treatments, and may require an experimental and more aggressive approach, said Dr. Ferrara. And it will also help guide treatment for patients with lower-risk GVHD who may be over-treated. This will allow us to personalize treatment at the onset of the disease. Future algorithms will prove increasingly useful to develop precision medicine for all SCT patients.
In order to capitalize on this discovery, Dr. Ferrara has created the Mount Sinai Acute GVHD International Consortium (MAGIC) which consists of a group of ten SCT centers in the US and Europe who will collaborate to use this new scoring system to test new treatments for acute GVHD. Dr. Ferrara and colleagues have also written a protocol to treat high-risk GVHD that has been approved by the FDA.
Co-collaborators included University of Michigan, University of Regensburg, and the Blood and Marrow Clinical Trials Network.
Follow this link:
Test Predicts Response to Early Treatment for Dangerous Complication of Stem Cells Transplants Used in Leukemia Patients
Cost of Stem Cell Treatment in Europe l Placid Answers
In this Video you can get the best answers for your questions about Stem Cell Treatment in Europe ! If you have any question about Stem Cell Treatment feel f...
By: placidways
Read more from the original source:
Cost of Stem Cell Treatment in Europe l Placid Answers - Video
SOUTH BEND, Ind.--- Mike and Katie have been a couple since college, but they've known each other much longer.
"We've been together forever," said Mike.
"I've actually known Mike since I was 5-years-old," said Katie.
A marriage and three kids later they've been through good times, and bad. The worst came nine-years-ago when Mike found out he had Huntington's disease.
Huntington's is a deadly, inherited disease that affects about 30,000 Americans; 150,000 more are at risk.
Until now there has been no hope for these patients, who typically die of the disease within 15 years of diagnosis.
"My father had it, said Mike. He died from it."
Huntington's causes uncontrollable movements and mental decline, there is no cure.
"Unfortunately, it ends in death, said Dr. Vicki Wheelock, a neurologist at UC Davis Health System. It's a fatal disease."
Now researchers are gearing up for a new trial in humans.
Visit link:
Doctors think stem cell injections could provide hope for Huntington disease patients
Six-year-old Pearland resident Tucker Beau Hyatt has known that he has been battling Monstritis for a long time. He has taken on the guise of Batman (shhh!) in order to beat it.
Monstritis was the then two-year-old Tuckers way of understanding his diagnosis of Systemic Juvenile Idiopathic Arthritis (JIA), a rare form of Rheumatoid Arthritis that affects about 300,000 children in the U.S. Over time, the membranes in the joints wear down, causing severe pain, loss of appetite and mobility.
Tuckers mother, Linsey Hyatt, recalls that it all started with a very high fever and a rash all over Tuckers body. We took him to the pediatrician thinking it was just some sort of infection, she said.
The blood work came back all over the place, and the youngster was referred to an Infectious Disease Specialist at Texas Tech.
The doctor took one look at Tucker and his chart and instantly knew what it was, Hyatt said.
By that time, Tucker had stopped eating and was unable to walk. We went to a rheumatoid specialist in Austin, which was the closest doctor to Midland, where we were living at the time, recalls Hyatt. They started him on chemotherapy, which was awful.
Tuckers mom and dad, Todd Hyatt, never stopped searching for a better solution to help their son, who was slowly wasting away from the disease. This is not a quick thing, said Linsey. Its slow and painful.
The Hyatts moved to Pearland in June of 2013 because of Todds job. They had become active with the Arthritis Foundation right after Tuckers diagnosis and attended an RAF luncheon in Austin featuring former Houston Oiler Earl Campbell, who suffers from osteoarthritis, in February 2014.
It was there that they first heard about Celltex, a company that facilitates stem cell therapy for RA, Multiple Sclerosis, Parkinsons and other autoimmune diseases.
We wanted to be able to tell Tucker Beau that we had done everything possible to help him, said Linsey.
Originally posted here:
Pearland boy makes remarkable recovery via stem cells
A Japanese Stem Cell Scientist At The Heart Of A Scandal Over False Claims And Fabricated Research Has Resigned.
Dr Haruko Obokata published supposedly groundbreaking research showing stem cells could be made quickly and cheaply.
There were irregularities in data, no other group in the world could repeat her findings and her own university concluded it could not be done.
In a statement Dr Obokata said: "I even can't find the words for an apology."
Stem cells can become any other type of tissue and hold great potential in medicine.
They are already being investigated to heal the damage caused by a heart attack and to restore sight.
But they are expensive and difficult to produce and one source - embryos - raises serious ethical questions.
'Major discovery'
Dr Obokata's scientific paper published in the prestigious journal Nature claimed that stem cells could be produced from normal adult cells by dipping them into acid for a 30-minute shock period.
The announcement of the creation of these "Stap" cells (stimulus-triggered acquisition of pluripotency) sent shockwaves around the world.
Read more:
Stem Cell Scandal Scientist Haruko Obokata Resigns